Market news Latest

End Stage Renal Disease Epidemiology Forecast to 2030

 Breaking News
  • No posts were found

End Stage Renal Disease Epidemiology Forecast to 2030

March 26
13:42 2020
End Stage Renal Disease Epidemiology Forecast to 2030

End Stage Renal Disease Epidemiology
DelveInsight’s “End Stage Renal Disease Epidemiology Forecast to 2030” report delivers an in-depth understanding of the disease, historical and forecasted End Stage Renal Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight launched a new report on End Stage Renal Disease Epidemiology Forecast to 2030

Some of the key facts of the report:-

1. End-Stage Renal Disease is more common in men than in women. The prevalence of chronic renal failure between the years 2007 and 2011 was higher in women (15.1%) than in men (12.1%).
2. About 15% of adults in the US are estimated to have chronic kidney disease. Chronic kidney disease can often be treated before it progresses to end-stage renal failure or leads to other health problems.
3. End-Stage Renal Disease prevalence in the US in 2007 was 1,698 cases per million population. In 2007, Japan also observed relatively high prevalence, i.e., 2,060 cases per million population of End-Stage Renal Disease, which included only people receiving maintenance dialysis.

Request for sample pages:- https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-epidemiology-forecast

 

Scope of the Report

  • The End Stage Renal Disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The End Stage Renal Disease Epidemiology Report and Model provide an overview of the risk factors and global trends of End Stage Renal Disease in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of End Stage Renal Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Sanfilippo Syndrome
  • The report provides the segmentation of the End Stage Renal Disease epidemiology

 

 

Reasons to buy

  • The End Stage Renal Disease Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global End Stage Renal Disease market
  • Quantify patient populations in the global End Stage Renal Disease market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for End Stage Renal Disease therapeutics in each of the markets covered
  • Understand the magnitude of End Stage Renal Disease population by its epidemiology
  • The End Stage Renal Disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

 

Request for sample pages:- https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-epidemiology-forecast

 

 

 Table of contents

1. Key Insights 

2. Executive Summary of End-Stage Renal Disease (ESRD)

3. End-Stage Renal Disease (ESRD): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. End-Stage Renal Disease (ESRD) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. End-Stage Renal Disease (ESRD) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. End-Stage Renal Disease (ESRD) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. End-Stage Renal Disease (ESRD) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. End-Stage Renal Disease (ESRD) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. End-Stage Renal Disease (ESRD) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. End-Stage Renal Disease (ESRD) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. End-Stage Renal Disease (ESRD) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. End-Stage Renal Disease (ESRD) Treatment and Management

6.2. End-Stage Renal Disease (ESRD) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

 

Related reports :-

 

End-Stage Renal Disease (ESRD) Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s End-Stage Renal Disease (ESRD) – Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/